OR WAIT null SECS
Check out the latest features and columns!
These five brands prove that pharma marketers can pull it together with compelling stories, and meaningful patient impact, even during a pandemic.
September's Executive Profile features Teva CEO Kåre Schultz
Biopharma leaders and experts gather to discuss the future of pharma collaboration and tackling critical public health needs—together.
Pharm Exec’s latest listing of the top global biopharma sales producers captures the critical business and public health balancing act that was required in the Year of COVID.
Read the profiles of 13 diverse leaders vital to the future of the biopharma industry.
With a complicated and challenging global picture greeting the new year, driven by the continuing pandemic and historic political and regulatory changes in the US and Europe, we outline eight diverse trends critical to biopharma’s future health and growth.
Highlighted Videos
September 14, 2021
Scientific advances are benefiting cancer patients, but it will take a pandemic-like response to ensure patients everywhere have access.
Though M&A activity and equity market outputs have been mixed, and pandemic challenges linger on, the outlooks for pharma and biotech remain stable—driven by R&D gains, record IPO levels.
Commercializing an orphan drug can be challenging, however, using a framework and a checklist that incorporates the right elements can prove beneficial.
Challenge assumptions and reset expectations when it comes to pre-launch SG&A investment to increase the odds of commercial success.
New drug aims to turn obesity into treatable chronic condition.
Peanut allergies raise fears among parents, teachers, but treatment is now available.
Hopeful new standard of care for advanced prostate cancer capitalizing on momentum.
The aggressive strategy behind a small company’s quick ascent in migraine market.
Latest disease-modifying market entrant for SMA addresses administration, access gaps.
